Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

With the world braced for an announcement of sweeping tariffs later today by President Donald Trump, analysts at ING have ...

Prosecutors in the US are seeking the death penalty for Luigi Mangione, the man detained in connection with the assassination ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock sat down with Dr Michael Bauer, CEO of Quantro Therapeutics, ...

EVERSANA – pharmaphorum's parent company – said it has met the standard to join Veeva's partner programme and will now be ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found ...

The Dermatology Drug Development Summit Europe returns for its 6th year as the premier industry forum dedicated to advancing ...